Fibrinolysis és érbetegségek.

Translated title of the contribution: Fibrinolysis and vascular diseases

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A wide array of in vitro fibrinolysis tests had been performed for a long period, suggesting defective fibrinolysis, mainly impaired tPA response and reserve as major, frequent abnormality, predecessor or causative factor of venous thromboembolism. However, these abnormalities were troublesome to reproduce, and more recently fibrinolytic activators and inhibitors received growing attention as rather atherogenic and less thrombogenic risk factors. Even if it is still not settled, lipoprotein(a) may interfere with fibrinolysis, and seems to carry atherogenic risk, too. The genetic polymorphism of fibrinogen, plasminogen, PAI-1 and some other compounds modifying circulating fibrinogen levels are also discussed in this review.

Original languageHungarian
Pages (from-to)1851-1855
Number of pages5
JournalOrvosi Hetilap
Volume137
Issue number34
Publication statusPublished - Aug 25 1996

Fingerprint

Fibrinolysis
Vascular Diseases
Fibrinogen
Lipoprotein(a)
Plasminogen
Plasminogen Activator Inhibitor 1
Venous Thromboembolism
Genetic Polymorphisms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fibrinolysis és érbetegségek. / Udvardy, M.; Boda, Z.

In: Orvosi Hetilap, Vol. 137, No. 34, 25.08.1996, p. 1851-1855.

Research output: Contribution to journalArticle

Udvardy, M & Boda, Z 1996, 'Fibrinolysis és érbetegségek.', Orvosi Hetilap, vol. 137, no. 34, pp. 1851-1855.
Udvardy, M. ; Boda, Z. / Fibrinolysis és érbetegségek. In: Orvosi Hetilap. 1996 ; Vol. 137, No. 34. pp. 1851-1855.
@article{2d572dd880ec4510983070d3f04f798e,
title = "Fibrinolysis {\'e}s {\'e}rbetegs{\'e}gek.",
abstract = "A wide array of in vitro fibrinolysis tests had been performed for a long period, suggesting defective fibrinolysis, mainly impaired tPA response and reserve as major, frequent abnormality, predecessor or causative factor of venous thromboembolism. However, these abnormalities were troublesome to reproduce, and more recently fibrinolytic activators and inhibitors received growing attention as rather atherogenic and less thrombogenic risk factors. Even if it is still not settled, lipoprotein(a) may interfere with fibrinolysis, and seems to carry atherogenic risk, too. The genetic polymorphism of fibrinogen, plasminogen, PAI-1 and some other compounds modifying circulating fibrinogen levels are also discussed in this review.",
author = "M. Udvardy and Z. Boda",
year = "1996",
month = "8",
day = "25",
language = "Hungarian",
volume = "137",
pages = "1851--1855",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "34",

}

TY - JOUR

T1 - Fibrinolysis és érbetegségek.

AU - Udvardy, M.

AU - Boda, Z.

PY - 1996/8/25

Y1 - 1996/8/25

N2 - A wide array of in vitro fibrinolysis tests had been performed for a long period, suggesting defective fibrinolysis, mainly impaired tPA response and reserve as major, frequent abnormality, predecessor or causative factor of venous thromboembolism. However, these abnormalities were troublesome to reproduce, and more recently fibrinolytic activators and inhibitors received growing attention as rather atherogenic and less thrombogenic risk factors. Even if it is still not settled, lipoprotein(a) may interfere with fibrinolysis, and seems to carry atherogenic risk, too. The genetic polymorphism of fibrinogen, plasminogen, PAI-1 and some other compounds modifying circulating fibrinogen levels are also discussed in this review.

AB - A wide array of in vitro fibrinolysis tests had been performed for a long period, suggesting defective fibrinolysis, mainly impaired tPA response and reserve as major, frequent abnormality, predecessor or causative factor of venous thromboembolism. However, these abnormalities were troublesome to reproduce, and more recently fibrinolytic activators and inhibitors received growing attention as rather atherogenic and less thrombogenic risk factors. Even if it is still not settled, lipoprotein(a) may interfere with fibrinolysis, and seems to carry atherogenic risk, too. The genetic polymorphism of fibrinogen, plasminogen, PAI-1 and some other compounds modifying circulating fibrinogen levels are also discussed in this review.

UR - http://www.scopus.com/inward/record.url?scp=0030601267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030601267&partnerID=8YFLogxK

M3 - Article

C2 - 8927337

AN - SCOPUS:0030601267

VL - 137

SP - 1851

EP - 1855

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 34

ER -